Media headlines about ProPhase Labs (NASDAQ:PRPH) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ProPhase Labs earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.507724855797 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
NASDAQ:PRPH opened at $2.99 on Friday. ProPhase Labs has a 52-week low of $1.78 and a 52-week high of $3.43. The stock has a market cap of $32.39, a price-to-earnings ratio of 3.78 and a beta of 0.01.
ILLEGAL ACTIVITY NOTICE: This news story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/prophase-labs-prph-receives-daily-coverage-optimism-score-of-0-15.html.
ProPhase Labs Company Profile
ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.